Terminated PHASE4 INTERVENTIONAL 2-arm NCT00308100

Hydroxyethyl Starch (130/0.4) for Intravascular Volume Therapy in Liver Transplantation

A Multicenter, Randomized, Open-Label, Parallel-Group, Albumin-Controlled Phase IV Study to Evaluate the Efficacy and Safety of Hydroxyethyl Starch (130/0.4) for Intravascular Volume Therapy in Patients Undergoing Liver Transplantation

Sponsor: Fresenius Kabi

Conditions Intraoperative Complications

Interventions 5% Albumin Hydroxyethylstarch 130/0.4

Updated 5 times since 2017 Last updated: Jan 14, 2009 Started: Oct 31, 2005 Primary completion: Jul 31, 2008 Completion: Jul 31, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Study is prematurely ended due to poor patient recruitment rate.

Other terminated trials from Fresenius Kabi

See all terminations from Fresenius Kabi

This PHASE4 trial investigates Intraoperative Complications and is currently terminated or withdrawn. Fresenius Kabi leads this study, which shows 5 recorded versions since 2005 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE4
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE4
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE4
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE4
Jan 2017 — Jun 2018 [monthly]

Terminated PHASE4

First recorded

Oct 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Fresenius Kabi

Data source: Fresenius Kabi

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China